Zepbound vs Mounjaro: Same Molecule, Two Different Authorizations
Content
Two names, two boxes, two prices, and a lot of people quietly assuming one must be the stronger version. In the Zepbound vs Mounjaro comparison, there isn’t one. They contain the same drug, made by the same company. The difference is what Health Canada authorized each one to do, and that is the part that actually affects you.
Key takeaways
Both contain tirzepatide. Chemically there is nothing to choose between them.
Health Canada authorized Zepbound for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity. It authorized Mounjaro to improve blood sugar control in type 2 diabetes.
Both start at 2.5 mg once weekly and both top out at 15 mg once weekly in adults.
In Canada the devices differ. Zepbound is supplied as a multidose prefilled pen, Mounjaro as single-dose prefilled pens.
That authorization difference, not the medicine, is usually what determines which one gets prescribed and how it is covered.
What tirzepatide is
Tirzepatide is a dual receptor agonist. It acts at the GLP-1 receptor, as several other medications in this category do, and also at the GIP receptor, glucose-dependent insulinotropic polypeptide. Both are hormones the gut releases after eating.
Acting at both separates tirzepatide from the semaglutide products, which act at GLP-1 alone. It affects insulin release, glucagon, stomach emptying, and appetite signalling.
Zepbound and Mounjaro contain that same molecule, at the same strengths, given as a weekly injection under the skin.
Zepbound vs Mounjaro: what is actually different
Zepbound
Mounjaro
Active ingredient
Tirzepatide
Tirzepatide
Device in Canada
Multidose prefilled pen
Single-dose prefilled pens
Authorized in Canada for
Chronic weight management, including weight loss and weight maintenance, in adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition; and moderate to severe obstructive sleep apnea in adults with obesity
Improving glycemic control in adults with type 2 diabetes, as monotherapy where metformin is inappropriate or in combination with other agents
Age range
Adults
Adults, and paediatric patients aged 10 to under 18
Starting dose
2.5 mg once weekly for 4 weeks
2.5 mg once weekly
Escalation
Increases of 2.5 mg after at least 4 weeks on the current dose
Increases of 2.5 mg after no less than 4 weeks on the current dose
Maintenance
5 mg, 10 mg or 15 mg weekly for weight management. 10 mg or 15 mg for sleep apnea
Titrated to glycemic control
Maximum
15 mg weekly
15 mg weekly in adults, 10 mg in patients aged 10 to under 18
Read down that table and the pattern is clear. The substance is identical. Who it is for is not.
What Health Canada authorized each one for
Zepbound is authorized for once-weekly use alongside a reduced-calorie diet and increased physical activity. The use is chronic weight management, covering both weight loss and weight maintenance. It applies to adults whose starting body mass index is 30 or above. It also applies from 27 to under 30, where at least one weight-related condition is present. The monograph gives examples of those conditions: high blood pressure, abnormal cholesterol, prediabetes, type 2 diabetes, obstructive sleep apnea and cardiovascular disease. It is separately authorized to treat moderate to severe obstructive sleep apnea in adults with obesity.
Mounjaro is authorized for once-weekly use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes. That includes use on its own, where metformin is not appropriate because of a contraindication or intolerance. It also covers several combinations: with metformin, with metformin and a sulfonylurea, with metformin and an SGLT2 inhibitor, or with basal insulin. It also covers paediatric patients aged 10 to under 18 with type 2 diabetes.
Those are the authorized uses in Canada. Prescribing outside them happens and is legal. It is a clinical judgment made by a licensed provider who knows your history, not something to plan around from an article.
One limitation on both monographs is worth stating: tirzepatide-containing products should not be taken together. Zepbound and Mounjaro are not to be combined.
How each one is dosed
Both follow the same escalation pattern, and both climb slowly because the gastrointestinal effects are worst while the dose is rising.
Zepbound starts at 2.5 mg once weekly for four weeks, then moves to 5 mg. From there it rises in 2.5 mg steps, after at least four weeks at each dose, to a maximum of 15 mg weekly. Maintenance is 5, 10 or 15 mg weekly for weight management, and 10 or 15 mg weekly for obstructive sleep apnea.
Mounjaro also starts at 2.5 mg once weekly. It rises in 2.5 mg steps, after no less than four weeks, where more glycemic control is needed. The adult maximum is 15 mg weekly. For patients aged 10 to under 18 it is 10 mg. The monograph advises caution above 5 mg in anyone weighing 60 kg or less. Neither product requires a dose adjustment for kidney impairment.
The pen difference, which is specific to Canada
In Canada, Zepbound comes as a multidose prefilled pen and Mounjaro as single-dose prefilled pens. That changes how you store and handle it, and how many devices you get each month. It says nothing about how well either works. American guides describe different devices, so they will not match what your pharmacy hands you.
Why the authorization difference is the part that affects you
Here is what people usually arrive frustrated about.
Because the two products carry different authorized uses, they sit in different places in the system. A prescription written for weight management and one written for type 2 diabetes are assessed as different requests. The pen contains the same molecule either way. Formularies, special authority criteria and private plan rules are built around the authorized indication rather than the ingredient.
That is why someone can be told one is covered and the other is not, and reasonably conclude the medicines must differ. They do not. The categories do.
So the useful conversation is not which one to ask for. It is which authorized indication applies to you, which a licensed provider determines.
Is one more effective than the other?
No trial has compared Zepbound against Mounjaro directly. There is also no mechanism by which one would outperform the other at the same dose, since they are the same drug at the same strengths.
What differs is what each development programme measured. The weight management authorization rests on trials in adults with obesity or overweight. Treatment ran up to 72 weeks, with at least 52 weeks at a maintenance dose. The sleep apnea authorization rests on separate trials in adults with obesity and moderate to severe obstructive sleep apnea. The Mounjaro programme measured blood sugar control in type 2 diabetes.
Different questions, different endpoints, one molecule. The outcome figures are in the monographs and worth reading with your provider rather than from a summary.
Side effects, warnings and contraindications
Both products share a side effect profile, because they share an active ingredient.
The most common adverse reactions are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, and reactions at the injection site. They are most pronounced while the dose is increasing and ease for most people once it settles.
Both monographs carry a warning relating to thyroid C-cell tumours observed in rodents. Both are also contraindicated in three groups. People with a personal or family history of medullary thyroid carcinoma. People with multiple endocrine neoplasia syndrome type 2. And anyone with known serious hypersensitivity to tirzepatide or to any component of the product.
Other warnings cover pancreatitis and gallbladder disease. Also kidney injury resulting from dehydration through gastrointestinal losses, and severe gastrointestinal reactions. Also complications of diabetic retinopathy in people with a history of it, and low blood sugar when combined with insulin or a sulfonylurea. Both monographs were updated in June 2026 with ophthalmologic warnings. Those include non-arteritic anterior ischemic optic neuropathy, a form of sudden vision loss caused by reduced blood flow to the optic nerve.
Pens should never be shared between people, even with the needle changed.
Safety and who should speak with a healthcare provider first
Speak with a licensed healthcare provider before starting either product if you:
have a personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2
have had pancreatitis or gallbladder disease
have type 1 diabetes, or a history of diabetic ketoacidosis
have diabetic retinopathy or any existing eye condition affecting the optic nerve
have kidney or liver problems
have a condition affecting how quickly the stomach empties, including gastroparesis
are pregnant, planning a pregnancy, or breastfeeding
take insulin or a sulfonylurea
have surgery or a procedure requiring anaesthetic scheduled, because delayed stomach emptying matters to the anaesthesia team
Get medical help right away for severe or persistent abdominal pain that may spread to the back, with or without vomiting. Do the same for sudden changes in vision, or for signs of a serious allergic reaction.
Frequently asked questions
Is Zepbound the same as Mounjaro?
They contain the same active ingredient, tirzepatide, from the same manufacturer, at the same strengths. They are sold as separate products because Health Canada authorized them for different uses, and in Canada they come in different pen formats. Chemically there is no difference.
Which one is authorized for weight in Canada?
Zepbound. It is authorized alongside a reduced-calorie diet and increased physical activity, for chronic weight management. That covers adults with a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition. Mounjaro is authorized for glycemic control in type 2 diabetes.
Are the doses the same?
Yes, the ladder is the same on both. A 2.5 mg start, 2.5 mg steps no sooner than every four weeks, and an adult ceiling of 15 mg. Where they part company is the destination. Zepbound names 5, 10 or 15 mg as maintenance, while Mounjaro is titrated to whatever controls blood sugar.
Can you switch from Mounjaro to Zepbound?
Switching is a prescriber decision, because it usually reflects a change in which authorized indication applies rather than a change of medication. Do not switch, overlap or adjust your own dose. The monographs also state that tirzepatide products should not be taken together.
Why is one covered and the other is not?
Coverage rules are built around the authorized indication rather than the ingredient. So a weight management prescription and a type 2 diabetes prescription are assessed differently, even though the drug is identical. What your specific plan covers is a question for your plan and your prescriber.
Does one work better?
No trial has compared them directly and there is no reason to expect a difference at the same dose. Their clinical programmes measured different things: weight and sleep apnea for one, blood sugar for the other. That is not the same as one being stronger.
The bottom line
Zepbound and Mounjaro are the same medicine wearing two labels. The difference lives entirely in what Health Canada authorized each to do. That in turn shapes who can be prescribed which, and how it gets paid for. If you’ve been comparing them looking for the stronger option, that isn’t the decision in front of you. The decision is which authorized use fits your situation, and that’s a clinical one.
You can read about Zepbound Kwikpen and Mounjaro Kwikpen, or speak with a licensed provider about which applies to you.
Disclaimer: This article is intended for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider with any questions about a medical condition or treatment.
Editorial Standards: At Rocky Health, we’ve made it our mission to support men and women with trustworthy, easy-to-understand medical and health information online. Read more about our editorial standards here.
